Search research articles
Contact Us
Filters
Showing results (701-710 of 738) with videos related to
Page
of 74
Sort By:
Archives of Internal Medicine
|
April 30, 2008
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans
Lawrence J Appel, Jackson T Wright, Tom Greene, et al.
European Heart Journal
|
August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
Hypertension (Dallas, Tex. : 1979)
|
November 23, 2012
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease
Mahboob Rahman, Tom Greene, Robert A Phillips, et al.
European Journal of Heart Failure
|
May 3, 2024
Identification and outcomes of KDIGO-defined chronic kidney disease in 1.4 million U.S. Veterans with heart failure
Samir S Patel, Venkatesh K Raman, Sijian Zhang, et al.
Journal of Diabetes Research
|
June 9, 2022
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial
Tamara K Young, Nigel D Toussaint, Gian Luca Di Tanna, et al.
Diabetes, Obesity & Metabolism
|
May 10, 2023
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials
Amy Kang, Brendan Smyth, Brendon L Neuen, et al.
Journal of the American College of Cardiology
|
June 21, 2023
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Muhammad Shariq Usman, Tariq Jamal Siddiqi, Stefan D Anker, et al.
Metabolic Syndrome and Related Disorders
|
March 29, 2008
Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome
Andrew J Drexler, Richard W Nesto, Martin J Abrahamson, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE Trial
George Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
JACC. Heart Failure
|
February 7, 2025
Outcomes of KDIGO-Defined CKD in U.S. Veterans With HFpEF, HFmrEF, and HFrEF
Samir Patel, Venkatesh K Raman, Charles Faselis, et al.
Page
of 74
Search research articles
Search
Showing results (701-710 of 738) with videos related to
Sort By:
Page
of 74
Archives of Internal Medicine
|
April 30, 2008
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans
Lawrence J Appel, Jackson T Wright, Tom Greene, et al.
European Heart Journal
|
August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
Hypertension (Dallas, Tex. : 1979)
|
November 23, 2012
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease
Mahboob Rahman, Tom Greene, Robert A Phillips, et al.
European Journal of Heart Failure
|
May 3, 2024
Identification and outcomes of KDIGO-defined chronic kidney disease in 1.4 million U.S. Veterans with heart failure
Samir S Patel, Venkatesh K Raman, Sijian Zhang, et al.
Journal of Diabetes Research
|
June 9, 2022
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial
Tamara K Young, Nigel D Toussaint, Gian Luca Di Tanna, et al.
Diabetes, Obesity & Metabolism
|
May 10, 2023
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials
Amy Kang, Brendan Smyth, Brendon L Neuen, et al.
Journal of the American College of Cardiology
|
June 21, 2023
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Muhammad Shariq Usman, Tariq Jamal Siddiqi, Stefan D Anker, et al.
Metabolic Syndrome and Related Disorders
|
March 29, 2008
Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome
Andrew J Drexler, Richard W Nesto, Martin J Abrahamson, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE Trial
George Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
JACC. Heart Failure
|
February 7, 2025
Outcomes of KDIGO-Defined CKD in U.S. Veterans With HFpEF, HFmrEF, and HFrEF
Samir Patel, Venkatesh K Raman, Charles Faselis, et al.
Page
of 74